NOPE FOR RELAPSED AGGRESSIVE DIFFUSE NON-HODGKINS-LYMPHOMA

被引：4

作者：

BEZWODA, WR

BEZWODA, MA

SEYMOUR, L

DANSEY, R

ARIAD, S

机构：

[1] Division of Clinical Hematology and Medical Oncology, Department of Medicine, University of Witwatersrand Medical School, Johannesburg

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 10卷 / 4-5期

关键词：

NON-HODGKINS LYMPHOMA; CHEMOTHERAPY; SALVAGE TREATMENT; MITOXANTRONE; ETOPOSIDE; VINCRISTINE; PREDNISOLONE;

D O I：

10.3109/10428199309148556

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Forty three patients with relapsed, diffuse aggressive lymphoma (Working Formulation Categories G to J) were treated with a combination chemotherapy regimen consisting of mitoxantrone 10 mg/m2 iv day 1, vincristine 1,4 mg/m2 iv day 1 and 14, prednisolone 50 mg/m2 p.o. days 1-5 and etoposide 100 mg/m2 p.o. days 1-5 of each cycle (NOPE). Fourteen patients (34%) achieved complete remission and another 6/43 (15%) achieved a partial response. Factors which significantly affected response were the presence of early stage, absence of systemic symptoms, non-bulky disease and serum LDH value <350 IU. Four patients are alive and in complete remission from 25+ to 45+ months after completion of therapy. Duration of response and survival was significantly influenced by the duration of the initial response to first chemotherapy. NOPE is an active and safe treatment regimen with a substantial complete remission rate in patients with relapsed non-Hodgkin's lymphoma.

引用

页码：329 / 333

页数：5

共 23 条

[1]

Fisher R.I., Gaynor E., Dahlberg S., Mize E.M., Oken M.M., Maywood I.L., A Phase III comparison of CHOP vs m BACOD vs Pro MACE Cyta BOM vs MACOP-B in patients with intermediate or high grade non-Hodgkin's lymphoma: Preliminary results of SWOG 8516 (Intergroup 0067), the National High-Priority Lymphoma Study, Proc. Am. Assoc. Clin. Oncol., 28, (1982)

[2]

Singer C.R.J., Goldstone A.H., Clinical studies of ABMT in non-Hodgkin's lymphoma, Clin. Haematol., 15, pp. 105-150, (1986)

[3]

Cornbleet M.A., Stuart-Harris R.C., Smith I.E., Coleman R.E., Rubens R.D., McDonald M., Mouridsen H.T., Rainer H., van Oosterom A.T., Smyth J.F., Mitoxantrone for the treatment of advanced breast Cancer: single agent therapy in previously untreated patients, Eur. J. Cancer Clin. Oncol., 20, pp. 1141-1146, (1984)

[4]

Bezwoda W.R., Bernasconi L., Hutchinson W.R., Winfield D., De Bock R., Mandelli F., Mitoxantrone for refractory and relapsed acute leukemias, Cancer, 66, pp. 418-422, (1990)

[5]

Fross-Abrahamsen A., Lenner P., Hendenus M., Landys K., Noppa H., Mitoxantrone in the treatment of patients with non-Hodgkin's lymphoma, Cancer Treat. Rep., 71, pp. 1209-1212, (1987)

[6]

Bajetta E., Buzzoni R., Valagussa P., Bonadonna G., Mitoxantrone: an active agent in refractory non-Hodgkin's lymphoma, Am. J. Clin. Oncol., 11, pp. 100-103, (1988)

[7]

Coltman J.F., Coltman C.A., Balcerzak T.M., Morrison S.P., Von Hoff F.S., Mitoxantrone in refractory non-Hodgkin's lymphoma: Southwest Oncology Group Study, Semin. Oncol., 11, pp. 50-53, (1984)

[8]

Jacobs P., King H.S., Cassidy F., Et al., VP 16–213 in the treatment of stage III and IV diffuse lymphocytic lymphoma of the large cell (histocytic) variety: an interim report, Cancer Treat. Rep., 65, pp. 987-993, (1981)

[9]

Scheulen M.E., Bremer K., Niederle N., Et al., Treatment of refractory malignant lymphomas with iphos-phamide/etoposide combination chemotherapy, Cancer Treat. Rev., 10, pp. 137-143, (1983)

[10]

Rosenberg S.A., Summary and Description of a Working Formulation for Clinical Usage, Cancer, 49, pp. 2112-2135, (1982)

← 1 2 3 →